Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapiesDenise M. Wolf, Laura van ‘t Veer, Christina Yau et al.|Cancer Cell|2022Cited by 335
Abstract P6-10-02: Assessing biomarkers to inform treatment de-escalation: Mid-treatment biopsy cellularity predicts pCR in the I-SPY 2 TrialSara J. Venters, W. Fraser Symmans, Yunn‐Yi Chen et al.|Cancer Research|2020Cited by 7
Abstract PS4-10: Serial MRI and pathology combined to select candidates for therapy de-escalation in the I-SPY 2 TRIALSara J. Venters, Nola M. Hylton, Wen Li et al.|Cancer Research|2021Cited by 1
Abstract A026: An alternative to HER2 IHC 0/1+/2+ status to predict which clinically HER2-negative patients will respond to anti-HER2 therapies: A rationale for the likely superiority of quantitative HER2 pathway RPPA measurementsJulia Wulfkuhle, Emanuel F. Petricoin, Denise M. Wolf et al.|Cancer Research|2024Cited by 0